MannKind Stock Forecast for 2023 - 2025 - 2030

Updated on 03/29/2024

Stock Rating
10
Price Target
$6.75
Consensus
Outperform
Upside
46.42%
Analysts
1
Stock Rating
10
Upside
46.42%
Analysts
1
Price Target
$6.75

MannKind Stock Forecast and Price Target

MannKind's most recent price target of $6.75 for 2024 was provided by renowned analysts over the past few months, with an average prediction of $6.75. If this prediction is correct, MannKind's stock could rise by 46.42 percent from its current trading price. The potential increase for the stock is $6.75 per share, with a possible range of $5.00 to $10.00. Even if you are not interested in MNKD stock, you should still be aware of its competitors.

$6.75

46.42% Upside

Buy
Buy

MannKind Fair Value Forecast for 2023 - 2025 - 2030

MannKind's Price has seen impressive growth In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $5.00 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.

2024 Fair Value Forecast
$5.00
2025 Fair Value Forecast
$5.56
2026 Fair Value Forecast
$6.18
2027 Fair Value Forecast
$6.87
2028 Fair Value Forecast
$7.64
2029 Fair Value Forecast
$8.50
2030 Fair Value Forecast
$9.45
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 9
$179.63 Buy/Sell $178.42 0.21%
AMGN Stock Forecast Amgen Outperform 4
$275.36 Buy/Sell $303.65 14.40%
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$75.32 Buy/Sell $87.82 10.20%
ALXN Stock Forecast Alexion Pharmaceuticals - 0
$182.50 Buy/Sell $177.38 -100.00%
BIIB Stock Forecast Biogen Outperform 10
$230.07 Buy/Sell $299.62 29.09%

MannKind Revenue Forecast for 2023 - 2025 - 2030

MannKind's Revenue has seen impressive growth In the last three years, rising from $65.14M to $198.96M – a growth of 205.43%. In the next year, analysts believe that Revenue will reach $268.71M – an increase of 35.06%. For the next seven years, the forecast is for Revenue to grow by 201.59%.

2024 Rev Forecast
$0.27B
2025 Rev Forecast
$0.35B
2026 Rev Forecast
$0.41B
2027 Rev Forecast
$0.44B
2028 Rev Forecast
$0.50B
2029 Rev Forecast
$0.55B
2030 Rev Forecast
$0.60B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BMRN Stock Forecast BioMarin Pharmaceutical Outperform 10
$86.00 Buy/Sell $111.56 26.40%
INCY Stock Forecast Incyte Outperform 9
$60.79 Buy/Sell $77.05 26.99%
ARNA Stock Forecast Arena Pharmaceuticals - 6
$99.99 Buy/Sell $100.00 -100.00%

MannKind Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BPMC Stock Forecast Blueprint Medicines Outperform 6
$89.47 Buy/Sell $85.71 11.77%
IOVA Stock Forecast Iovance Biotherapeutics Buy 4
$15.10 Buy/Sell $20.42 68.87%
ACAD Stock Forecast ACADIA Pharmaceuticals Outperform 6
$24.13 Buy/Sell $33.78 32.62%

MannKind Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$0.05B
2025 FCF Forecast
$0.11B
2026 FCF Forecast
$0.14B
2027 FCF Forecast
$0.16B
2028 FCF Forecast
$0.16B
2029 FCF Forecast
$0.18B
2030 FCF Forecast
$0.18B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
FOLD Stock Forecast Amicus Therapeutics Outperform 7
$12.13 Buy/Sell $17.90 64.88%
CCXI Stock Forecast ChemoCentryx - 8
$51.99 Buy/Sell $52.00 -100.00%
CBAY Stock Forecast CymaBay Therapeutics Hold 8
$32.44 Buy/Sell $27.73 0.18%

MannKind EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, MannKind's EBITDA has seen an increase, rising from $-22.90M to $14.58M. This represents a growth of 163.67%. According to 0 prominent analysts, MannKind's EBITDA will fall by 203.06% in the next year, reaching $-15.03M. By 2030, professionals believe that MannKind's EBITDA will decrease by 256.72%, reaching $-22.85M – a concerning trend for the company.

2024 EBITDA Forecast
$-15026634.00
2025 EBITDA Forecast
$0.00B
2026 EBITDA Forecast
$-6343781.35
2027 EBITDA Forecast
$-644951.10
2028 EBITDA Forecast
$-1541605.13
2029 EBITDA Forecast
$-6534607.20
2030 EBITDA Forecast
$-22850214.44
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ARWR Stock Forecast Arrowhead Pharmaceuticals Outperform 7
$29.40 Buy/Sell $52.00 87.07%
VKTX Stock Forecast Viking Therapeutics Buy 5
$63.44 Buy/Sell $34.00 73.39%
DRNA Stock Forecast Dicerna Pharmaceuticals - 7
$38.01 Buy/Sell $35.06 -100.00%

MannKind EBIT Forecast for 2023 - 2025 - 2030

MannKind's EBIT has seen growth In the last three years, going from $-24.79M to $10.59M – a gain of 142.72% In the next year, analysts believe that EBIT will reach $56.07M – an increase of 429.46%. For the next seven years, the forecast is forEBIT to grow by 2003.12%.

2024 EBIT Forecast
$0.06B
2025 EBIT Forecast
$0.11B
2026 EBIT Forecast
$0.14B
2027 EBIT Forecast
$0.17B
2028 EBIT Forecast
$0.18B
2029 EBIT Forecast
$0.20B
2030 EBIT Forecast
$0.22B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CLDX Stock Forecast Celldex Therapeutics Buy 11
$46.54 Buy/Sell $63.29 65.45%
VCEL Stock Forecast Vericel Buy 8
$44.59 Buy/Sell $42.58 18.86%
ARDX Stock Forecast Ardelyx Buy 11
$8.49 Buy/Sell $9.94 56.07%

MannKind EPS Price Prediction Forecast for 2023 - 2025 - 2030

MannKind's EPS has seen impressive growth In the last four years, rising from $-0.20 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $0.09 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.

2024 EPS Forecast
$0.09
2025 EPS Forecast
$0.26
2026 EPS Forecast
$0.46
2027 EPS Forecast
$0.45
2028 EPS Forecast
$0.44
2029 EPS Forecast
$0.50
2030 EPS Forecast
$0.57
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AGIO Stock Forecast Agios Pharmaceuticals Outperform 9
$30.80 Buy/Sell $40.00 41.23%
DVAX Stock Forecast Dynavax Technologies Outperform 11
$12.97 Buy/Sell $25.00 88.90%
XNCR Stock Forecast Xencor Outperform 6
$23.13 Buy/Sell $37.91 47.00%